Status:
ACTIVE_NOT_RECRUITING
Study of CM310 in Adolescent Subjects With Atopic Dermatis
Lead Sponsor:
Keymed Biosciences Co.Ltd
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
12-18 years
Phase:
PHASE3
Brief Summary
This is a multi-center, single arm, open label phase 3 study to evaluate the safety and efficacy of CM310 in children patients with moderate-to-severe atopic dermatitis.
Eligibility Criteria
Inclusion
- Have the ability to understand the study and voluntarily sign a written informed consent form (ICF).
- Subjects who must complete the evaluation of Week 18 of the main study.
- With Atopic Dermatitis.
Exclusion
- Any major surgery planned during the research period.
- Subjects with potential fertility do not agree to adopt efficient contraceptive measures throughout the entire study period; Pregnant or breastfeeding women, or women planning to conceive or breastfeed during the study period.
- With any circumstance that the subject is not suitable to participate in this study.
Key Trial Info
Start Date :
August 2 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 30 2026
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT06495229
Start Date
August 2 2024
End Date
August 30 2026
Last Update
October 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's hospital
Beijing, China